Protagonist Therapeutics, Inc.
US ˙ NasdaqGM ˙ US74366E1029

Introduction

This page provides a comprehensive analysis of the known insider trading history of Suneel Gupta. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Suneel Gupta has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PTGX / Protagonist Therapeutics, Inc. Chief Development Officer 267,433
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Suneel Gupta. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases PTGX / Protagonist Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PTGX / Protagonist Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-12-03 PTGX Gupta Suneel 30,000 5.1300 30,000 5.1300 153,900 363 24.1600 570,900 370.96

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTGX / Protagonist Therapeutics, Inc. Insider Trades
Insider Sales PTGX / Protagonist Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PTGX / Protagonist Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-11-26 PTGX Gupta Suneel 19,191 45.5000 19,191 45.5000 873,190 91 35.0900 -199,778 -22.88
2024-11-25 PTGX Gupta Suneel 103,437 46.0400 103,437 46.0400 4,762,239

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTGX / Protagonist Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Suneel Gupta as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-11-27 2024-11-26 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 450 267,433 0.17 12.17 5,476 3,254,660
2024-11-27 2024-11-26 4 PTGX Protagonist Therapeutics, Inc
Common Stock
S - Sale -19,191 266,983 -6.71 45.50 -873,190 12,147,726
2024-11-27 2024-11-26 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 30,000 286,174 11.71 12.17 365,100 3,482,738
2024-11-27 2024-11-25 4 PTGX Protagonist Therapeutics, Inc
Common Stock
S - Sale -103,437 256,174 -28.76 46.04 -4,762,239 11,794,251
2024-11-27 2024-11-25 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 85,000 359,611 30.95 7.80 663,000 2,804,966
2024-11-27 2024-11-25 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 45,000 274,611 19.60 8.02 360,900 2,202,380
2024-11-27 2024-11-25 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 45,000 229,611 24.38 7.38 332,100 1,694,529
2024-02-28 2024-02-26 4 PTGX Protagonist Therapeutics, Inc
Common Stock
F - Taxes -4,282 183,285 -2.28 29.53 -126,447 5,412,406
2024-01-11 2024-01-09 4 PTGX Protagonist Therapeutics, Inc
Common Stock
S - Sale X -5,000 187,567 -2.60 25.00 -125,000 4,689,175
2024-01-11 2024-01-09 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 5,000 192,567 2.67 7.38 36,900 1,421,144
2024-01-04 2024-01-02 4 PTGX Protagonist Therapeutics, Inc
Common Stock
A - Award 19,250 187,567 11.44
2023-10-23 2023-10-19 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 20,000 168,317 13.48 7.38 147,600 1,242,179
2023-06-02 2023-05-31 4 PTGX Protagonist Therapeutics, Inc
Common Stock
F - Taxes -4,150 148,037 -2.73 26.07 -108,190 3,859,325
2023-06-02 2023-05-31 4 PTGX Protagonist Therapeutics, Inc
Common Stock
A - Award 12,000 152,187 8.56
2023-01-18 2023-01-16 4 PTGX Protagonist Therapeutics, Inc
Common Stock
A - Award 20,625 138,187 17.54
2022-04-26 2022-04-26 4 PTGX Protagonist Therapeutics, Inc
Stock Option (right to buy)
M - Exercise -40,000 70,000 -36.36
2022-04-26 2022-04-26 4 PTGX Protagonist Therapeutics, Inc
Common Stock
M - Exercise 40,000 117,561 51.57 7.38 295,200 867,600
2022-03-02 2022-02-28 4 PTGX Protagonist Therapeutics, Inc
Common Stock
F - Taxes -649 77,007 -0.84 24.28 -15,758 1,869,730
2022-02-17 2022-02-15 4 PTGX Protagonist Therapeutics, Inc
Stock Option (right to buy)
A - Award 75,000 75,000
2022-02-17 2022-02-15 4 PTGX Protagonist Therapeutics, Inc
Common Stock
A - Award 12,500 77,656 19.18
2021-02-26 2021-02-26 4 PTGX Protagonist Therapeutics, Inc
Stock Option (right to buy)
A - Award 80,000 80,000
2021-02-26 2021-02-26 4 PTGX Protagonist Therapeutics, Inc
Common Stock
A - Award 12,000 63,987 23.08
2020-02-28 2020-02-28 4 PTGX Protagonist Therapeutics, Inc
Stock Option (right to buy)
A - Award 85,000 85,000
2019-12-03 2019-12-03 4 PTGX Protagonist Therapeutics, Inc
Common Stock
P - Purchase 30,000 49,500 153.85 5.13 153,900 253,935
2019-03-04 2019-02-28 4 PTGX Protagonist Therapeutics, Inc
Stock Option (right to buy)
A - Award 45,000 45,000
2019-03-04 2019-02-28 4 PTGX Protagonist Therapeutics, Inc
Common Stock
A - Award 7,500 17,500 75.00
2019-01-16 2019-01-15 4 PTGX Protagonist Therapeutics, Inc
Stock Option (right to buy)
M - Exercise 110,000 110,000
2019-01-09 3 PTGX Protagonist Therapeutics, Inc
Common Stock
20,000
2019-01-09 3 PTGX Protagonist Therapeutics, Inc
Common Stock
20,000
2019-01-09 3 PTGX Protagonist Therapeutics, Inc
Common Stock
20,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)